Antares Pharma Announces the Issuance of a New U. S. Patent for OTREXUP™
News Jul 01, 2013
Antares Pharma, Inc. announced that it has received a Notice of Issuance from the U. S. Patent Office for patent number 8,480,631 entitled “Hazardous Agent Injection System.” The claims of this patent are directed toward an injection system for methotrexate and also a method for treating rheumatoid arthritis and other autoimmune diseases using an auto-injector or similar device for subcutaneous delivery of methotrexate. Upon its issuance on July 9, 2013, the patent will provide nearly seventeen (17) years of intellectual property protection for OTREXUP™.
“This patent issuance represents a major milestone in our long-term strategy intended to provide comprehensive intellectual property protection for OTREXUP™,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer and co-inventor of the patent. “The granting of this broad and comprehensive patent is an important achievement in our commercialization strategy and one of a number of patent applications we have filed addressing the use of an auto-injector platform in combination with a wide range of product candidates, including those in our growing pipeline, such as QST being developed for testosterone replacement therapy.”
Computational Model Underlines Need for Personalised Approach to SepsisNews
A computational model of the human immune system has enabled researchers to explore the challenges of tackling sepsis.READ MORE
Allergies and Asthma Possibly Linked to Female HormonesNews
Fluctuations in female sex hormones could play a role in the development of allergies and asthma, a major review of evidence suggests. Analysis of studies involving more than 500,000 women highlights a link between asthma symptoms and key life changes such as puberty and menopause. Further investigation could help explain why asthma is more common in boys than girls in childhood, but more common in teenage girls and women following puberty.READ MORE